1752.Tw

The company maintains a relatively strong liquidity position, with a current ratio of 1.4, indicating that it has sufficient short-term assets to cover its short-term liabilities. However, its liquidity is rated as medium, and it has a negative net cash position after accounting for total debt, which may pose some near-term financial constraints. The company's debt-to-equity ratio is 0.26, suggesting a conservative capital structure with limited leverage.

In terms of profitability, the company's return on equity (ROE) is 9.84%, and its return on assets (ROA) is 6.39%, both of which are above the industry median for pharmaceutical firms. These metrics indicate that the company is effectively utilizing its equity and assets to generate returns, which is a positive sign for investors.

The company's revenue is primarily concentrated in a single geographic region, with no disclosed segment breakdown. This lack of diversification may expose the company to regional economic or regulatory risks. There is no available data on revenue by business segment, which limits the ability to assess the performance of individual product lines or therapeutic areas.

Looking ahead, the company is expected to maintain a stable revenue trajectory, with no significant growth or decline projected in the next fiscal year. The company's capital expenditures are negative, indicating that it is generating more cash from operations than it is spending on new assets, which may suggest a mature business with limited expansion needs.

The company's risk profile is characterized by a low dilution potential, with no near-term pressure for share issuance or dilution. However, the negative net cash position after subtracting total debt is a key flag that may warrant further monitoring. The company has not disclosed any recent events such as major filings, earnings calls, or strategic announcements that would significantly impact its operations or financial position.